ECGLIVE
92 bpmAnali-X / Clinical research programme
Advancing earlier, explainable recognition of ICU deterioration.
Anali-X is Hale-X’s first clinical research programme, applying biological state modelling of the individual patient to ICU deterioration and sepsis.
RESEARCH STAGE · NOT APPROVED FOR CLINICAL OR DIAGNOSTIC USE
REAL-TIME ICU SYSTEMSynthetic research illustration
FROM SIGNALS TO PATIENT CONTEXT01 · BEDSIDEOne patient. Many live signals.
ICU R:0042SpO₂LIVE
96 % CONTINUOUS MONITORING DEIDENTIFIED
Arterial pressureSTREAM
118/64 mmHgVentilationLIVE
18 rpmBlood gasnew result
Medicationexposure updated
Lactatetrend changing
02 · HALE-XConnect the whole picture.
ACTIVEONE PATIENTContinuous
contextnow · before · next
TIMELINESYSTEMSEVIDENCEGAPScontextnow · before · next
01Synchronisesignals through time
02Connectsystems and events
03Interpretchange with evidence
03 · ANALI-X RESEARCH VIEWFollow the patient trajectory.
RESEARCHPatient state through timeLIVE WINDOW
−6 h−4 h−2 hNOW
STATEWhat is happening now?
TRAJECTORYWhat is changing?
EVIDENCEWhat supports it?
UNCERTAINTYWhat remains unresolved?
Clinician remains in control
Illustrative system architecture using synthetic data. Research stage. Not approved for clinical or diagnostic use.
Research objectives
Three questions guide the programme.
State
Can longitudinal data support a coherent view of changing biological state?
Trajectory
Can that state help researchers study emerging deterioration before it is obvious?
Explanation
Can outputs retain the evidence and uncertainty needed for meaningful review?
Development pathway
A staged route to clinical evidence.
PLATFORM FOUNDATION
Core Replica architecture
The longitudinal patient state modelling foundation is operational.
IN PREPARATION
Retrospective ICU feasibility study
Protocol, funding and data governance work are underway; study execution and data access have not yet started.
NEXT PHASE
Prospective evaluation
Progression will depend on retrospective findings, clinical partnerships and the required approvals.
Regulatory status
MDR Rule 11 classification assessment underway. Current working hypothesis: Class IIb, subject to final intended purpose and formal regulatory assessment.
Research collaboration